Whereas factors such as biological sex [94], age [95], previous myeloablative treatments [95], and comorbidities (e.g. diabetes) [96] mediate mobilisation failure after G-CSF therapy, the strongest predictor of successful HSC collection is high pre-procedure peripheral blood HSC count [20]. The gene discussed is CSF3; the disease is diabetes mellitus.